For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Morphine sulfate - Pain
PAD Profile : Morphine sulfate - Pain
Traffic Light Status
Status 1 of 4.
- Immediate release tablets
- Oral solution
- Oro-dispersible
Status 2 of 4.
- Injection
- Solution for infusion
Status 3 of 4.
- Capsules (slow release)
- Granules (slow release)
- Tablets (slow release)
Status 4 of 4.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Oxycodone
- Co-codamol (Codeine phosphate/paracetamol)
- Tramadol hydrochloride
- Oxycodone hydrochloride/naloxone hydrochloride
- Fentanyl
- Tramadol hydrochloride
- Tramadol hydrochloride
- Paracetamol
- Codeine phosphate
- Dihydrocodeine tartrate
- Buprenorphine
- Pregabalin
- Gabapentin
- Dronabinol/cannabidiol
- Co-dydramol (Dihydrocodeine/paracetamol)
- Ibuprofen
- Meptazinol hydrochloride
- Pethidine hydrochloride
- Diamorphine hydrochloride
- Alfentanil hydrochloride
- Co-dydramol (Dihydrocodeine/paracetamol)
- Co-dydramol (Dihydrocodeine/paracetamol)
- Nefopam hydrochloride
- Papaveretum
- Aspirin
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Zomorph® is the locally preferred brand of morphine sulfate modified release (12-hourly formulation).
Branded prescribing is recommended for morphine sulfate MR preparations by UKMi (see branded prescribing guidance below). Prescribers should identify patients currently prescribed generic preparations and change to the preferred branded product – Zomorph®.
Key points for consideration:
- Prescribers should be aware that there is no 5mg Zomorph® available so may wish to initiate MST® as the preferred brand if 5mg presentation is required.
- Switching MST® to Zomorph® is an option as they are bioequivalent.
- MXL is the only brand available for 24 hour preparations
- Zomorph® capsules can be opened and administered orally or via a tube – granules / capsules should not to be crushed
A stepped approach to pain management is recommended. Morphine is the 1st line treatment option where a strong opioid is indicated. Please refer to the guidelines attached.
It is recommended that morphine oral modified release (MR) preparations are prescribed by BRAND - see UKMI Branded Prescribing Recommendations document below. Patients currently receiving generically written prescriptions for morphine MR preparations should be reviewed with a view to changing the prescribing to a more cost-effective brand.
Please note that Zomorph® capsules can be opened up for patients who are unable to swallow.
Ensure a patient agreement is completed by the patient (see below) prior to a trial of Morphine